• Abbott flagged new real-world studies on its Cologuard stool DNA screening test, with results already presented at ACG 2026.
• Research linked completing the test to fewer colorectal cancer diagnoses versus non-completion in a nationwide cohort of average-risk adults.
• A separate case-control analysis associated prior screening completion with lower odds of death following a colorectal cancer diagnosis.
• Data support the commercial case for stool-based screening by tying usage to long-term outcomes, not just test performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.